Provention Bio, Inc. (PRVB)
(Delayed Data from NSDQ)
$3.98 USD
+0.18 (4.74%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.92 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
[PRVB]
Reports for Purchase
Showing records 1 - 20 ( 48 total )
Industry: Medical - Biomedical and Genetics
Sanofi Acquisition Announced; Downgrading to Neutral and PT Up to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 12.50
Industry: Medical - Biomedical and Genetics
Cash Replenished; TZIELD U.S. Launch Advancing; Lowering PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 5.00
Industry: Medical - Biomedical and Genetics
Awaiting Teplizumab Regulatory Decision; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 5.00
Industry: Medical - Biomedical and Genetics
Teplizumab Decision Postponed; Equity Financing; Lowering PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 5.00
Industry: Medical - Biomedical and Genetics
Positive PRV-101 Initial Clinical Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 5.00
Industry: Medical - Biomedical and Genetics
FDA Accepts Teplizumab Biologics License Application; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 5.00
Industry: Medical - Biomedical and Genetics
Teplizumab Resubmitted to FDA; 2021 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 5.00
Industry: Medical - Biomedical and Genetics
Teplizumab BLA Resubmission Timeline Clarified; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 5.00
Industry: Medical - Biomedical and Genetics
Teplizumab FDA Response Taking Shape; 3Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 5.00
Industry: Medical - Biomedical and Genetics
Price: 25.00
Industry: Medical - Biomedical and Genetics
Teplizumab Resubmission Timing Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Industry: Medical - Biomedical and Genetics
Teplizumab Substudy Data Near-Term; 2Q21 Financials; Reducing PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Industry: Medical - Biomedical and Genetics
Complete Response Letter Received, as Expected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Industry: Medical - Biomedical and Genetics
Favorable Teplizumab Advisory Committee Vote; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Industry: Medical - Biomedical and Genetics
Advisory Committee Meeting Imminent; 1Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Industry: Medical - Biomedical and Genetics
Teplizumab FDA Update Indicates More Work Needed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Industry: Medical - Biomedical and Genetics
Regulatory Concerns Could Delay Teplizumab Approval; Reducing PT to $27
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Industry: Medical - Biomedical and Genetics
Teplizumab Advisory Committee Meeting Date Confirmed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Industry: Medical - Biomedical and Genetics
Teplizumab Advisory Committee Meeting Near-Term; 2020 Financials; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Industry: Medical - Biomedical and Genetics
PRV-3279 Licensing Deal; Teplizumab Pricing Revised; Raising PT to $34
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00